NEW YORK: Ogilvy PR has won the US account for the Pfizer pain franchise, which includes arthritis drugs Celebrex and Bextra, the pharmaceutical company said today.The agency will be AOR for all PR activities involving the two drugs, according to Paul Ewing, Pfizer director of PR. Terms were not disclosed. Shire Health will handle PR for the pain products outside the US, including Dynastat, a painkiller not approved here. Four agencies pitched for the account this summer. In recent weeks, Pfizer?s pain franchise has been subject to the same inquiries as Merck?s Vioxx. Ewing denied that the current questions about cox-2 inhibitors delayed the announcement. Pfizer has already undertaken an advertising initiative for Celebrex to promote its safety. In a previous interview, Michal Fishman, director of public affairs for Pfizer US pharmaceuticals, declined to discuss PR plans around the advertising campaign. But she noted that the messages would be consistent. Both MS&L, which had held the Celebrex account, and Weber Shandwick, which held Bextra, decided not to re-pitch. This is the second time Pfizer has consolidated PR for one of its drug franchises. WPP won the heart franchise in January.